GANX

Gain TherapeuticsC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

20%

Probability

Target price

$2.40

Analysis reference price unavailable

Analysis 2026-10-16 · RankAlpha Sentiment Codex

Most likely

Base case

45%

Probability

Target price

$1.10

Analysis reference price unavailable

Analysis 2026-10-16 · RankAlpha Sentiment Codex

B-

Bear case

35%

Probability

Target price

$0.45

Analysis reference price unavailable

Analysis 2026-10-16 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-10-16

AI commentary

The October company update is clinically encouraging but also resets Phase 2 timing later. The packet provides no reliable post-update price-reaction, analyst-revision, options, short-interest, employee, or sufficiently covered social measures; zero-valued sentiment fields denote unavailable data, not neutral readings. Low coverage and the negative deterministic directional prior favor cautious monitoring.

RankAlpha Sentiment Codex - 2026-10-16

Open full AI memo

Evidence flagged

small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report

Impact

tentative

Confidence

AI events

2026-11-30catalystRevised rexaceract Phase 2 protocolHigh impact

Gain said it expects to submit a new Phase 2 protocol to the FDA in the coming weeks. Confirmation would clarify the development path, but the company has moved its planned trial start from Q3 2026 to Q1 2027. The date here is a monitoring estimate, not a company deadline [#8-K-2026-10-01]. SEC filing

2027-03-31eventRexaceract Phase 2 initiationHigh impact

The company now expects to begin its Parkinson’s disease Phase 2 trial in Q1 2027. Starting on the revised schedule would reduce execution uncertainty; another delay would compound the setback [#8-K-2026-10-01]. SEC filing

2027-03-31catalystFunding and runway extensionHigh impact

Gain reported $13.1 million of cash at June 30, 2026, expected funding into Q2 2027, and substantial doubt about its ability to continue as a going concern. Financing terms or a funded collaboration could materially change the outlook; dilution remains a significant risk. The date is a monitoring estimate [#SEC-10Q-2026-08-11]. SEC filing

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-10-16 • Updated nightlySource: Internal modelMethodology